Holdbrook Mark J. 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 4, 2021
Insider Transaction Report
Form 4
Holdbrook Mark J.
V.P., Clinical Affairs
Transactions
- Award
Stock Option (right to buy)
2021-03-02+14,300→ 14,300 totalExercise: $34.72Exp: 2031-03-02→ Common Stock (14,300 underlying)
Footnotes (1)
- [F1]Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan. 25% of the option shares shall vest and become exercisable on March 2, 2022, and 1/48th of the option shares shall vest and become exercisable each month thereafter for a period of 3 years.